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Introduction
Gene  expression  can  be  greatly  diversified  by  alternative 
splicing of precursor mRNAs (premRNAs) in higher eukaryotic 
cells. Cell type–specific and developmental regulation of alter-
native splicing plays an important role in cell differentiation and 
functional specification. Although the vast majority of mamma-
lian genes undergo alternative splicing, not every resultant 
transcript functionally encodes protein. Genomics studies have 
indicated that 35% of alternatively spliced transcripts acquire 
premature termination codons due to reading frame shift and 
are thereby eliminated by the nonsense-mediated decay (NMD) 
pathway  (Lejeune  and  Maquat,  2005;  McGlincy  and  Smith, 
2008). This alternative splicing–coupled NMD (AS-NMD) 
regulation not only allows manipulating mRNA levels at the 
post-transcriptional level, but also provides a means of gene   
expression control in a regulatory loop.
Alternative splicing is regulated by a variety of RNA-
binding proteins. Interplay between these splicing regulatory 
factors and corresponding cis-elements determines splice site 
utilization (Wang and Burge, 2008; Chen and Manley, 2009; 
Tejedor and Valcárcel, 2010). In addition, cooperative or antag-
onistic action between the regulatory factors modulates alterna-
tive splicing. Because most trans-acting factors are ubiquitously 
expressed, their relative abundance or activity in a cell is thus 
important for alternative splicing regulation (Long and Caceres, 
2009; Licatalosi and Darnell, 2010). In principal, the activity, 
stability, or subcellular localization of splicing factors may be 
modulated by their post-translational modification upon induc-
tion of cellular signaling pathways (Blaustein et al., 2007; 
Lynch, 2007; Stamm, 2008). Besides, expression of a substan-
tial pool of splicing factors is post-transcriptionally regulated 
via AS-NMD (Wollerton et al., 2004; Boutz et al., 2007b), and 
therefore, their abundance may be controlled by an autoregu-
latory loop or by other splicing regulators (Stamm 2008; Sun 
et al., 2010).
The  polypyrimidine  tract-binding  (PTB)  protein  is  a   
master regulator of alternative splicing in mammalian cells   
and also functions at several other steps of mRNA metabolism   
(Sawicka et al., 2008). PTB contains four RNA recognition motifs 
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elements adjacent to the regulated exons and thereby antago-
nizes the suppressive effect of PTB in -TM exon selection 
(Lin and Tarn, 2005). Although RBM4 is ubiquitously ex-
pressed, its abundance is particularly high in muscle and heart 
(Lin and Tarn 2005). Upon induction of differentiation in 
mouse C2C12 myoblasts, RBM4 is phosphorylated and a pro-
portion of total RBM4 transiently translocates to the cytoplasm, 
where it may function in translation control (Lin et al., 2007). 
Nevertheless,  RBM4  may  have  nuclear  functions  during 
muscle cell differentiation. The observation that RBM4 regu-
lates exon selection of -TM provides a hint that it has potential 
in modulating muscle cell type–specific splicing of other tran-
scripts during myogenesis. Moreover, the expression of RBM4 
in muscle cells prompted us to investigate whether it partici-
pates in regulation of PTB expression.
Results
AS-NMD–mediated down-regulation  
of PTB/nPTB during myogenesis
In neurons, expression of PTB and nPTB is mutually exclusive, 
with PTB primarily expressed in precursor cells and glia, and 
nPTB in post-mitotic neurons (Boutz et al., 2007b). Suppres-
sion of nPTB expression in nonneuronal cells primarily results 
from PTB-mediated AS-NMD of the nPTB transcript (Spellman 
et al., 2007). In differentiated muscle cells, however, expres-
sion of both PTB and nPTB is suppressed (Boutz et al., 2007b). 
A recent report indicated that nPTB down-regulation in dif-
ferentiated muscle cells is in part controlled by microRNAs 
(Boutz et al., 2007b). However, whether the AS-NMD path-
way is also responsible for down-regulation of nPTB and 
(Oberstrass et al., 2005) that confer RNA binding activity and 
mediate PTB homodimer formation (Oberstrass et al., 2005; 
Lamichhane et al., 2010). PTB favors binding to UUCU ele-
ments that often exist within the polypyrimidine tract of an   
intron; therefore, PTB usually functions as a splicing suppressor 
by competing off the splicing factor U2AF and the U2 small 
nuclear ribonucleoprotein complex from the 3 end of the intron 
(Sharma  et  al.,  2005).  Moreover,  PTB  modulates  alternative 
splicing of a large number of transcripts (Amir-Ahmady et al., 
2005; Gama-Carvalho et al., 2006). Thus, control of PTB expres-
sion level is important for splicing regulation in cells (Boutz et al., 
2007b; Makeyev et al., 2007; Spellman et al., 2007). Indeed, 
PTB is particularly down-regulated via various mechanisms 
during neuron and muscle development (Boutz et al., 2007a; 
Makeyev et al., 2007). Notably, PTB has an autoregulatory   
activity; overexpression of PTB activates the skipping of exon 11 
of its own premRNA, yielding premature termination codon–
containing  isoforms  that  are  subsequently  targeted  to  NMD 
(Wollerton et al., 2004). Analogously, PTB cross-regulates the 
expression of its neuronal analogue nPTB by promoting exon 10 
exclusion in nPTB transcripts (Makeyev et al., 2007; Spellman 
et al., 2007). However, whether PTB can be regulated by any 
other splicing regulatory factors via AS-NMD is not yet known.
The RNA-binding motif 4 (RBM4) protein is a multi-
functional protein that has been shown to act at least in prem-
RNA splicing regulation and translation control (Lin and Tarn, 
2005, 2009; Lin et al., 2007). We have previously screened for 
target mRNAs of human RBM4 and verified that RBM4 could 
specifically promote the selection of skeletal muscle–specific 
exons in -tropomyosin (-TM; Lin and Tarn, 2005). In this 
regard, RBM4 competes with PTB binding to intronic CU-rich 
Figure 1.  AS-NMD of PTB/nPTB transcripts occurs during 
myogenesis. C2C12 cells were cultured under differentia-
tion conditions for 0–3 d. Before harvest, cells were mock 
treated or treated with cycloheximide (CHX). Total RNA 
was isolated for RT-PCR analysis followed by probing with 
32P-labeled primers specific to PTB exon 10 (lanes 1–8) or 
nPTB exon 9 (lanes 9–16). The identity of the transcripts 
is indicated. Asterisks represent nonspecific bands. Exon 
exclusion  efficiency  (percentage)  is  represented  by  the   




10 for nPTB) to total RNA species; the aver-
aged values shown below the lanes were obtained from 
three independent experiments.511 A splicing cascade during myogenesis • Lin and Tarn
preferentially to CU-rich sequences (Lin et al., 2007; Lin and 
Tarn, 2009), it might serve such a role. Indeed, RBM4 was   
detectable,  and  its  expression  level  even  increased  slightly 
throughout differentiation in concert with diminished expres-
sion of PTB/nPTB (Fig. 2; total RBM4). Moreover, phosphory-
lation of RBM4 was significantly enhanced during C2C12 
differentiation (Fig. 2; phos-RBM4), as reported (Lin et al., 
2007). Therefore, unlike PTB/nPTB, RBM4 may act as a func-
tional splicing regulatory factor in muscle cells. If so, any sub-
stantive increase in the molar ratio or the relative activity of 
RBM4 to PTB/nPTB might profoundly change alternative splicing 
patterns in differentiating muscle cells.
RBM4 modulates alternative splicing of 
PTB and nPTB
In nonneuronal cells, PTB suppresses nPTB expression by in-
ducing exon 10 skipping in nPTB premRNA (Spellman et al., 
2007). Indeed, excess PTB can also modulate its own prem-
RNA splicing (Wollerton et al., 2004). Our notions that RBM4 
shares similar binding elements with PTB (Lin and Tarn, 2005) 
and that their expression and/or activity might be reciprocally 
regulated during C2C12 cell differentiation (Fig. 2) prompted 
us to examine whether RBM4 may regulate alternative splicing 
of PTB/nPTB. We overexpressed FLAG-tagged RBM4 in C2C12 
cells and treated cells with cycloheximide. RT-PCR analysis 
showed that RBM4, like PTB, increased the abundance of two 
exon 11–skipped transcripts of endogenous PTB (Fig. 3 A, 
lanes 6 and 7), and promoted PTB exon 11 skipping in a dose-
dependent manner (Fig. S2 A). Analogously, both RBM4 and 
even PTB in muscle cells has not been excluded. To assess this 
possibility, we performed RT-PCR to detect PTB and nPTB 
transcripts in C2C12 cells. Two major PTB transcripts, i.e., full-
length PTB-4 and exon 9–skipped PTB-1, were expressed in non-
differentiated C2C12 myoblasts (Fig. 1, lane 1). The expression 
level of these two transcripts did not change significantly or 
was minimally reduced as cells differentiated (lanes 2–4). 
Although NMD was blocked by translation inhibitor cyclo-
heximide or overexpression of the dominant-negative mutant 
of  the  NMD  factor  Upf1  (Upf1-DN)  in  cells  (Banihashemi   
et al., 2006), the exon 11–skipped products, PTB-1
11 and 
PTB-4
11, were detectable, and their expression level was   
increased throughout differentiation (Fig. 1, lanes 5–8; and 
Fig. S1 A). Although the exon 10–skipped mRNA isoform of 
nPTB could be detected in nondifferentiated cells, its abundance 
also gradually increased throughout differentiation in the pres-
ence of cycloheximide (Fig. 1, lane 9–16). This result sug-
gested that AS-NMD contributes at least in part to controlling 
PTB and nPTB expression during muscle cell differentiation.
Expression of RBM4 and PTB/nPTB 
proteins in differentiating myoblasts
Using immunoblotting, we observed that the protein level of 
both PTB and nPTB gradually diminished throughout C2C12 
cell differentiation (Fig. 2), which was consistent with previous 
reports (Boutz et al., 2007a). We thus assumed that AS-NMD 
of PTB and nPTB transcripts is activated or maintained by a 
splicing factor(s) expressed in differentiated muscle. Because 
RBM4 is expressed in differentiated C2C12 cells and binds 
Figure 2.  Differential expression of RBM4 and PTB/nPTB proteins during muscle cell differentiation. C2C12 cells were cultured under differentiation condi-
tions for 0–3 d. Protein samples were fractionated on separate gels followed by immunoblotting sequentially with antibodies specific for PTB, nPTB, and 
tubulin (top) or with RBM4, phosphorylated RBM4, and tubulin (bottom). Values given below the bands represent relative protein expression levels of each 
protein throughout differentiation. The graph shows the change in the ratio of total RBM4 to (n)PTB during cell differentiation.JCB • VOLUME 193 • NUMBER 3 • 2011   512
muscle cell differentiation, may not be a critical factor for in-
ducing PTB/nPTB exon skipping.
Next,  we  examined  whether  RBM4  is  essential  for 
PTB/nPTB splicing regulation during muscle cell differentiation. 
Transient expression of a short hairpin RNA targeting mouse 
RBM4 mRNA depleted 60% of endogenous RBM4 protein in 
C2C12 cells (Fig. 3 B, immunoblot). Such partial depletion of 
RBM4 reduced differentiation-induced exon skipping of PTB 
and nPTB by 35 and 26%, respectively (Fig. 3 B, lanes 8, 
16, and graph). A similar result was obtained by using another 
RBM4 shRNA (shRNA2) (Fig. S3 A). This result indicated that 
RBM4 participates in alternative splicing regulation of PTB/nPTB 
during C2C12 differentiation.
Moreover, using immunoblotting, we observed that the 
levels of PTB and nPTB proteins decreased upon overexpres-
sion of FLAG-tagged RBM4 (Fig. 4, lane 2), but they increased 
PTB could activate exon 10 skipping of endogenous nPTB 
(Fig. 3 A, lanes 14 and 15). Nevertheless, ASF had no effect on 
PTB or nPTB alternative exon selection (lanes 8 and 16). This 
result provided a hint that the presence of RBM4 during muscle 
cell differentiation could potentially activate PTB/nPTB exon 
skipping, which may result in down-regulation of their protein 
expression. Because RBM4 is significantly phosphorylated 
upon differentiation induction (Fig. 2; Lin et al., 2007), we 
asked whether phosphorylation of RBM4 has any effect on its 
splicing activity. As shown in Fig. S2, both nonphosphorylat-
able (SA) and phosphomimetic (SD) RBM4 proteins could   
activate exon skipping of PTB/nPTB (Fig. S2 B). However, the 
slightly lower activity of RBM4-SD was perhaps due to its rela-
tive high abundance in the cytoplasm as compared with the 
wild-type RBM4 (Fig. S2 C). Nevertheless, we apparently con-
cluded that phosphorylation of RBM4, which occurs during 
Figure 3.  RBM4 activates exon skipping of PTB/nPTB premRNAs and is involved in differentiation-induced alternative splicing of PTB/nPTB. (A) C2C12 
cells were transiently transfected with the mock vector or vector expressing FLAG-tagged PTB, RBM4, or ASF. (B) C2C12 cells were transfected with the 
mock vector (lanes 1–4) or RBM4-targeting shRNA expression vector (lanes 5–8), and then cultured in growth (G) or differentiation (D) medium. Before 
harvest, cells were mock treated or treated with cycloheximide (CHX). RT-PCR analysis and calculation of exon exclusion efficiency were performed in 
Fig. 1. Asterisks represent nonspecific bands. Immunoblotting was performed with anti-FLAG (A) and with anti-RBM4 and anti-tubulin in parallel on the 
same membrane (B).513 A splicing cascade during myogenesis • Lin and Tarn
efficiency in growing C2C12 cells (Fig. 5 C, lanes 1, 3, 5, and 7). 
As anticipated, these two exons were excluded in differenti-
ated C2C12 cells (lane 2, reporter E11), suggesting that PTB 
exon 11 with its upstream and downstream intronic UCEs could 
properly respond to differentiation signals in a heterologous   
reporter. Further, such an exon exclusion was only minimally 
impaired in the reporter E11D (lane 4) but was completely 
abolished in reporters E11U and DU (lanes 6 and 8). This 
result suggested that the upstream intronic sequence was most 
important for differentiation-induced exon skipping, whereas 
the sequence downstream of exon 11 contributed less to such 
splicing regulation activity.
As  anticipated  and  observed  under  cell  differentiation 
conditions, overexpression of either RBM4 or PTB could result 
in exclusion of PTB exon 11 and -TM exon 9b in the E11 re-
porter mRNA (Fig. 5 D, lanes 2 and 3). RBM4 overexpres-
sion could suppress such exon inclusion of both E11D and 
E11U, albeit with reduced efficiency (lanes 7 and11), whereas 
only E11D but not E11U was still responsive to PTB-
mediated exon 11 exclusion (lanes 6 and10). Therefore, both 
upstream and downstream introns of exon 11 might contain the 
elements  responsive  to  RBM4-mediated  regulation,  whereas 
the activity of PTB largely depended on the upstream elements. 
Nevertheless, ASF had no effect on either reporter examined 
(lanes 4, 8, 12, and 16). The notion that splicing of E11U 
could be modulated by RBM4 but not by differentiation (Fig. 5 C, 
lane 6; and Fig. 5 D, lane 11) was somewhat intriguing. We ap-
parently reasoned that overexpressed RBM4 might force exon 
11 skipping via the elements in the downstream intron or even 
in exon 11 (see following paragraph).
It has been predicted that the CU-rich exon 11 of PTB 
harbors a PTB recognition motif (Wollerton et al., 2004), which 
appeared to coincidentally overlap with a putative RBM4 bind-
ing site (Fig. 5 A). Therefore, to test whether RBM4 and PTB 
act on such a composite element, we mutated its sequence in 
the E11 reporter (Fig. 5 E, diagram). RT-PCR analysis showed 
when RBM4 was down-regulated by either one of the tested 
shRNAs (Fig. 4, lane 4; Fig. S3 B). This result coincided with the 
effect of RBM4 in promoting alternative splicing of PTB/nPTB 
to yield potential NMD substrates (Fig. 3). Overall, our results 
suggested a role for RBM4 in controlling PTB/nPTB expression 
by modulating the alternative splicing of PTB/nPTB transcripts 
during muscle cell differentiation.
RBM4 regulates PTB exon selection by 
binding to CU-rich elements
Next,  we  attempted  to  explore  the  mechanism  of  RBM4- 
mediated PTB splicing regulation by using minigene assay. We 
observed that overexpression of RBM4 could result in exon 11 
skipping of a PTB minigene transcript that encompassed exon 
10–12 of the mouse PTB (Fig. S4). Because RBM4 favors to 
bind CU-rich sequences, we suspected that RBM4 regulates 
PTB exon 11 selection via its surrounding CU-rich ultracon-
served elements (UCEs; Wollerton et al., 2004; Ni et al., 2007). 
Indeed, an intronic CU-rich element immediately upstream of 
PTB exon 11 most resembles the consensus binding site for 
RBM4 (Fig. 5 A; Lin and Tarn, 2005). Therefore, to evaluate 
whether the UCEs surrounding PTB exon 11 are necessary and 
sufficient for RBM4-mediated splicing regulation in a heterolo-
gous sequence context, we inserted PTB exon 11 with or with-
out flanking intronic sequences into the -TM reporter to 
replace its RBM4-responsive exon 9a (Fig. 5 B; Lin and Tarn, 
2005). Because -TM exons 9a and 9b are concomitantly in-
cluded or excluded (Lin and Tarn, 2005), we performed RT-PCR 
using two sets of primers (Fig. 5 B) to assess the expression 
of  the  resulting  -TM–PTB  chimeric  reporters  in  C2C12 
cells. One RT-PCR product spanning the 5 SV40 sequence 
and -TM intron 8 (e8/i8) represented the reporter premRNAs, 
whereas another product amplified by using SV40 and -TM 
exon 9b primers corresponded to the spliced products (e8/11/9b). 
The result showed that all four tested reporter transcripts in-
cluded PTB exon 11 and following -TM exon 9b with similar 
Figure 4.  RBM4 modulates PTB/nPTB protein expression 
levels in C2C12 cells. C2C12 cells were mock transfected 
(lanes  1  and  3)  or  transfected  with  vector  expressing 
FLAG-RBM4 (lane 2) or RBM4 shRNA (lane 4). Immuno-
blotting was performed on independent membranes (sep-
arated by blank space) with pairs of antibodies in parallel 
that were specific for the FLAG epitope (FLAG-RBM4) or 
endogenous proteins as indicated.JCB • VOLUME 193 • NUMBER 3 • 2011   514
CU-rich elements (Lin and Tarn, 2005). We assumed that RBM4 
and PTB may antagonistically regulate some other muscle-specific 
splicing events and that an increase in the RBM4/PTB ratio 
throughout myoblast differentiation may have functional and 
physiological significance. To test this possibility, we examined 
the effect of RBM4 on several premRNAs regulated by PTB 
(Amir-Ahmady et al., 2005; Gama-Carvalho et al., 2006). 
FLAG-tagged  RBM4,  PTB,  or ASF  was  overexpressed  in 
C2C12 cells followed by RT-PCR analysis using primers spe-
cific for validated PTB targets, including palladin, cardiac tro-
ponin T (cTnT), insulin receptor (IR), and ryanodine receptor 
(RyR; Fig. 6 A, diagram). Indeed, all these mRNAs underwent 
alternative  exon  utilization  upon  myoblast  differentiation  to 
generate muscle cell–specific isoforms (Fig. 6 A, lane 2). Inter-
estingly, overexpression of RBM4 promoted splicing toward 
differentiation-induced isoforms of all tested transcripts (lane 5). 
However, PTB acted oppositely to RBM4 in alternative exon 
selection of these myocyte-expressed transcripts (lane 4). ASF 
had no significant effect on the examined reporters except for 
that the mutant exon 11 was no longer skipped in differentiated 
C2C12 cells (not depicted) and, accordingly, was not responsive 
to RBM4 or PTB-mediated control (Fig. 5 E, RT-PCR).
An immunoprecipitation RT-PCR analysis revealed that 
RBM4 associated with the -TM transcripts in cells (unpub-
lished  data).  Moreover,  recombinant  RBM4  might  directly 
bind PTB exon 11 and its upstream and downstream CU-rich 
sequences (Fig. S5). Therefore, our results together indicated 
that RBM4 and PTB may regulate alternative exon selection   
in PTB mRNA via binding to respective recognition sites 
throughout the entire UCEs of PTB, including exon 11 and its 
flanking introns.
RBM4 and PTB differentially regulate 
muscle-specific alternative splicing
To  this  point  our  data  indicated  that  RBM4  down-regulates 
PTB/nPTB expression in differentiated C2C12 cells. Indeed, 
RBM4 and PTB oppositely regulate skeletal muscle–specific 
-TM splicing via competing for binding to common intronic 
Figure 5.  Ultraconserved elements of PTB are responsible for RBM4-mediated regulation of PTB AS-NMD. (A) Diagram showing the mouse PTB genomic 
fragment encompassing exon 11 and a part of its adjacent introns. Putative intronic RBM4 and PTB binding sites are indicated by red and blue vertical 
lines, respectively. The CU-rich element in exon 11 is indicated by a thick orange line. The PTB genomic fragments of the pE11 and its derived reporters   
(see panel B) are depicted. (B) Diagrams showing the chimeric reporters in which exon 9a of human -TM was replaced by mouse PTB exon 11   
with different lengths of the flanking intron sequences. (C) Each reporter, as indicated, was transiently transfected into C2C12 cells. Cells were cultured 
under growth (G) or differentiation (D) conditions for 1 d. Cells were treated with cycloheximide before harvest. For C–E, total RNA was isolated from the 
transfectants and subjected to RT-PCR using a forward primer specific to SV40 and reverse primers specific to -TM intron 8 (i8) and exon 9b (9b) to yield 
products e8/11/9b and e8-i8, respectively. The PCR products were probed with 
32P-labeled SV40 primer. Exon 11 exclusion of the reporter transcripts 
is represented by the ratio of e8/11/9b to e8-i8; the averaged values shown below the lanes were obtained from three independent experiments, and 
then normalized to that of mock transfectants. GAPDH was used as the control. (D) Each indicated reporter was cotransfected with an expression vector 
encoding FLAG-tagged PTB, RBM4, or ASF. (E) Diagram showing the mutant pE11 reporter in which the CU-rich sequence of exon 11 was mutated.   
The reporter assay for lanes 1–4 and 5–12 was performed as in C and D, respectively.515 A splicing cascade during myogenesis • Lin and Tarn
antagonizing the suppressive effect of PTB, irrespective of 
exon exclusion during muscle cell differentiation (Fig. 6 C).
Finally, to understand more about how RBM4 and PTB 
modulate muscle cell–specific alternative splicing, we searched 
for candidate genes that encode CU-rich elements near the mus-
cle cell–specific exons. We chose the genes encoding fast skele-
tal TnT (fTnT), myocardin, and MEF2c for further analysis. 
RBM4 promoted skipping of fTnT exons 7 and 8 but included 
exon 11 of myocardin (Fig. 6 A, lane 5), confirming that RBM4 
promoted muscle-specific isoform expression. MEF2c under-
goes alternative splicing in differentiated muscle cells to select 
exon 2 but exclude exon  (Hakim et al., 2010). We observed 
the same results in C2C12 cells after induction of differentiation 
(lane 2), as reported (Hakim et al., 2010), and also in cells that 
overexpressed RBM4 or PTB (lanes 4 and 5). Therefore, in 
the case of MEF2c, PTB functioned similarly to RBM4; the 
cTnT (lane 6). Next, to examine whether RBM4 may directly 
regulate the above tested PTB substrates, we knocked down 
PTB by using the shRNA strategy (Boutz et al., 2007b). We first 
evaluated alternative splicing of -TM in C2C12 cells under 
growth and differentiation conditions. The result showed that 
inclusion of the terminal exons 9a and 9b of -TM was signifi-
cantly induced upon differentiation (Fig. 6 B, lane 2), which   
allowed  expression  of  the  skeletal  muscle–specific  isoform. 
Knockdown of PTB could somewhat relieve the suppression   
of exon 9a/9b inclusion in proliferating C2C12 cells (lane 3). 
Nevertheless, overexpression of RBM4 in the absence of PTB 
greatly promoted exon 9a/9b inclusion (lane 4), suggesting a 
likely direct role RBM4 in -TM exon selection. Furthermore, 
we demonstrated that overexpression of RBM4 could reverse 
the effect of PTB-induced exclusion of -TM exon 9a/9b and 
cTnT exon 5 in C2C12 cells, supporting a role for RBM4 in   
Figure 6.  RBM4 and PTB differentially modulate alternative splicing of muscle cell–specific exon selection. (A) Diagrams showing the alternatively spliced 
regions of premRNAs encoding mouse PTB, nPTB, palladin, fTnT, MEF2c (exons 1/2 and ), cTnT, IR, Ryr, and myocardin. M and NM represent muscle-
enriched and nonmuscle-enriched mRNA isoforms, respectively. C2C12 cells were cultured in growth (lane 1) or differentiation (lane 2) medium for 3 d or 
transfected with the mock vector (lane 3) or expression vector of FLAG-tagged PTB, RBM4, or ASF (lanes 4–6). Total RNA was subjected to RT-PCR using 
gene-specific primers (Table II), and the PCR products were blotted for probing with a 
32P-labeled forward primer. Efficiency of muscle-enriched isoform 
production is reflected by the ratio of M/NM; the values shown below the lanes are averaged from three independent experiments. (B) C2C12 cells were 
transfected with the empty vector (lanes 1 and 2) or the PTB shRNA expression vector (lanes 3 and 4) and cultured under growth (lanes 1, 3, and 4) or 
differentiation (lane 2) conditions for 2 d. RT-PCR was performed to examine terminal exon inclusion of -TM as described in Lin and Tarn (2005). GAPDH 
was used as the control. Protein samples were fractionated on separate gels followed by immunoblotting sequentially with anti-PTB and anti-tubulin (middle) 
or with anti-RBM4 and anti-tubulin in parallel (bottom). (C) C2C12 cells were transfected with the pTM reporter and then cultured under growth (lane 1)   
or differentiation (lane 2) conditions for 3 d. In addition to the pTM reporter, C2C12 cells were also transfected with an empty vector (lane 3) or the 
FLAG-PTB expression vector alone (lane 4) or together with increasing amounts of the FLAG-RBM4 expression vector (lanes 5–7). -TM and cTnT transcripts 
were detected as in B and A, respectively. GAPDH was used as the control. Values represent the relative level of -TM normalized to GAPDH in for each 
sample. Immunoblotting was performed using anti-FLAG. In all panels, band sizes for RT-PCR products are shown in parentheses.JCB • VOLUME 193 • NUMBER 3 • 2011   516
expression of some of these factors may be regulated at the 
post-transcriptional level. Recent findings that the expression of 
a set of UCE-containing mammalian splicing regulatory factors 
is regulated by AS-NMD suggest the existence of splicing regu-
lation cascades (Ni et al., 2007). Therefore, the levels of these 
factors in cells can be controlled by regulated splicing.
PTB is ubiquitously expressed in mammalian tissues 
but is replaced by nPTB in neurons. PTB expression is down-
regulated in neuronal cells by both transcriptional silencing and 
microRNA 124–mediated translation suppression (Makeyev 
et al., 2007). In nonneuronal cells, PTB suppresses nPTB ex-
pression via AS-NMD (Spellman et al., 2007). However, a re-
duction of PTB level in neurons allows reactivation of nPTB 
expression (Boutz et al., 2007b; Makeyev et al., 2007). Because 
PTB and nPTB regulate the expression of overlapping but dis-
tinct sets of genes, the switch from PTB to nPTB provides an 
important  role  in  reprogramming  alternative  splicing  during 
neuronal development. In differentiated muscle cells, both PTB 
and nPTB are down-regulated (Boutz et al., 2007b). Although it 
has been demonstrated that muscle-specific microRNAs are re-
sponsible for PTB/nPTB suppression in muscles (Boutz et al., 
2007a), we detected exon 10/11–skipped PTB/nPTB transcripts 
in differentiated C2C12 cells upon NMD inactivation (Fig. 1). 
Therefore, differentiation-induced PTB/nPTB suppression might 
also involve AS-NMD. Note that expression of RBM4 contin-
ued during muscle cell differentiation (Fig. 2; Lin et al., 2007). 
Overexpression of RBM4 promoted PTB/nPTB exon skipping, 
similar to that observed with cell differentiation, whereas knock-
down of RBM4 suppressed exon skipping and accordingly in-
creased the levels of PTB and nPTB (Figs. 3 and 4). Our result 
indicates that RBM4 contributes at least in part to the reduction of 
PTB and nPTB levels during C2C12 cell differentiation. Therefore, 
analogous to the scenario that PTB suppresses nPTB expression 
in nonneuronal cells, RBM4 down-regulates its functional antago-
nists, namely PTB and nPTB, also by AS-NMD during muscle cell 
differentiation. Moreover, RBM4-mediated splicing control of PTB 
and nPTB reveals a novel splicing cascade in mammalian cells.
We have previously shown that overexpression of RBM4 
promotes the distal 5 splice site utilization of the adenovirus 
implication of differential regulation of exon selection by PTB 
is discussed below. In total, our results suggest that RBM4 and 
PTB regulate the same set of transcripts but generally act oppo-
sitely to control muscle cell–specific exon selection.
Overexpression of RBM4 promotes muscle 
cell differentiation
The above data indicate that RBM4 modulates alternative splic-
ing of muscle cell transcripts to produce skeletal muscle–specific 
isoforms. We therefore examined whether RBM4 acts as a mus-
cle cell differentiation-promoting factor. Immunoblotting analy-
sis  showed  that  transient  overexpression  of  FLAG-tagged 
RBM4 in C2C12 myoblasts increased the level of myosin 
heavy chain (MHC), a differentiation marker of muscles (Fig. 7 A). 
Immunofluorescence coincidently showed significant high 
abundance of MHC in RBM4-overexpressed cells (Fig. 7 B). 
Moreover,  we  observed  that  cells  underwent  morphological 
change toward myocyte phenotype upon RBM4 overexpression 
(unpublished data). However, the possibility that RBM4 pro-
motes muscle cell differentiation not only via alternative splic-
ing but also via other steps of mRNA metabolism cannot be 
completely excluded.
Discussion
Here we report that down-regulation of PTB/nPTB in differenti-
ated muscle cells may, at least in part, involve the AS-NMD 
pathway. RBM4 activated alternative exon skipping of PTB/
nPTB transcripts and was responsible for differentiation-induced 
alternative splicing of PTB/nPTB in myoblasts. Moreover, 
RBM4 and PTB shared a common set of targets but differen-
tially modulate their exon selection. Therefore, the observed   
increase in the RBM4/(n)PTB ratio during muscle cell dif-
ferentiation might result in a change in global alternative splic-
ing patterns.
Cell differentiation involves not only transcriptional re-
programming but also regulated alternative splicing (Kuyumcu-
Martinez and Cooper, 2006; Fu et al., 2009; Loya et al., 2010). 
The latter may require cell type–specific splicing regulators;   
Figure 7.  Overexpression of RBM4 promotes muscle cell differentiation. (A) C2C12 cells were mock transfected or transiently transfected with the ex-
pression vector encoding FLAG-tagged RBM4. Immunoblotting was performed with antibodies against myosin heavy chain (MHC), FLAG-epitope, and 
-tubulin. (B) C2C12 cells were cultured under growth (G) or differentiation (D) conditions or transiently overexpressed FLAG-tagged RBM4. Indirect   
immunofluorescence was performed with anti-MHC. Bar, 10 µm.517 A splicing cascade during myogenesis • Lin and Tarn
mechanism, RBM4 perhaps activates exon skipping of PTB/
nPTB as well as fTnT and -actinin (Table I). These and other 
possibilities remain to be investigated.
Recent studies have globally mapped the binding sites of 
several splicing regulatory factors including PTB on mRNA tar-
gets, facilitating a clearer picture of splicing regulation (Sharma 
and Black, 2006; Ule et al., 2006). PTB in general functions as 
a splicing suppressor to activate exon skipping via binding to 
intronic CU-rich elements near regulated exons (Valcárcel and 
Gebauer, 1997; Wagner and Garcia-Blanco, 2001; Spellman   
et al., 2005). Because these elements are often located within or 
near the polypyrimidine tract, the binding of PTB likely per-
turbs spliceosome assembly at the 3 end of the intron. While 
binding to both upstream and downstream introns, multimer-
ized PTB may loop out the exon and hence prevent exon recog-
nition by the spliceosome (Lamichhane et al., 2010). Further, 
PTB can activate exon utilization when its binding sites are   
located distal to regulated exons (Ni et al., 2007; Castle et al., 
2008; Sawicka et al., 2008). Our reporter assay indicated that 
PTB suppresses its own exon 11 inclusion likely via binding to 
both exon 11 and its upstream intron (Fig. 5), which conforms 
to the rule of PTB-mediated exon exclusion (Ni et al., 2007; 
Castle et al., 2008). However, PTB also promoted inclusion of 
the alternative exons of palladin, fTnT, and -actinin (Fig. 5 and 
unpublished data), but, intriguingly, these exons have similar 
features to those that are skipped by PTB. Therefore, how PTB 
distinguishes various exons and determines their fate remains 
an enigma and still requires future investigation.
This  study  shows  that  RBM4  regulates  a  number  of 
muscle-specific exons, which are also the targets of PTB (Fig. 6). 
E1a transcript (Lai et al., 2003). In this regard, RBM4 and the 
SR protein ASF act oppositely on 5 splice site selection, but the 
underlying mechanism has not been investigated. A search for 
cellular targets of RBM4 has suggested that it has preference for 
CU-rich sequences (Lin and Tarn, 2005; Lin et al., 2007). In-
deed, RBM4 activates skeletal muscle–specific exons of -TM 
by competing with PTB for binding to the CU-rich elements 
downstream of its regulated exons (Lin and Tarn 2005). Consis-
tent with previous observations (Lin and Tarn, 2005; Lin et al., 
2007), RBM4 may bind multiple CU-rich elements within and 
adjacent to exon 11 of PTB (Fig. 5 and Fig. S5). Using trun-
cated and mutant PTB reporters, we observed that that RBM4 
perhaps binds simultaneously to exon 11 and its upstream or 
downstream intron (Figs. 5 and 8 A). However, in contrast to its 
effect on -TM exon selection, RBM4 excluded exon 11 from 
PTB transcripts. As compared with PTB exon 11, -TM exon 9a 
appears to lack CU-rich motifs. Consistent with this observa-
tion, most of the alternative exons examined that are included 
upon overexpression of RBM4, such as in the premRNAs for 
cTnT, IR, Ryr, and vinculin, also lack potential RBM4 binding 
sites (Table I). The exception is myocardin, in which the alter-
native exon 11 harbors CU-rich motifs but flanking introns are 
deficient in C/U residues. We thus assumed that, in addition to 
out-competing negative regulators, when RBM4 binds to in-
tronic elements nearby a regulated exon, it may promote exon 
inclusion by facilitating association of the spliceosome with the 
adjacent splice sites (Fig. 8 B). However, when RBM4 binds 
simultaneously to the alternative exon and either flanking intron, 
it may interfere with the nearby spliceosome association with 
the splice sites and thus excludes the exon (Fig. 8 B). By this 
Table I.  RBM4 and PTB differentially modulate alternative splicing of a set of muscle-specific transcripts
Transcript AS exon
1 Muscle isoform CU-rich motifs
Exon Intron
RBM4 and PTB show the same effect;  
both promote the expression of muscle-specific isoforms.
PTB e11 Skip + +
nPTB e10 Skip + +
MEF2c 1/2 Include 2 + (2) + (2)
MEF2c  Skip  +
RBM4 and PTB show the opposite effect;  
RBM4 promotes the expression of muscle-specific isoforms
RBM4 skips; PTB includes
Palladin e4 Skip  +
fTnT E6 and 7 Skip +
2 +
-Actinin
3 e19 Skip + +
RBM4 includes; PTB skips
-Tropomyosin e9a Include (sk
4)  +
cTnT e5 Include  +
IR e11 Include  +
Ryr e83 Include  +
Myocardin e11 Include + 
Vinculin
3 e19 Include  +
1AS exon, alternatively spliced exon.
2The CU-rich sequence is located between exons 6 and 7, but is not present in the exons.
3Data for the RT-PCR analysis are not shown in Fig. 6.
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San Diego, La Jolla, CA), respectively. The His-tagged PTB expression vec-
tor was constructed by cloning the human PTB-coding region into pET-32a 
(QIAGEN). The pTM-8/9a/9b reporter (hereafter abbreviated as pTM) 
containing a fragment of the human -tropomyosin gene was described 
previously (Lin and Tarn, 2005). The mouse PTB genomic fragments con-
taining exon 11 flanked by different lengths of its adjacent intron sequences 
were used to replace exon 9a of pTM. The resulting vectors were full-
length pE11, and pE11D, U, and UD containing truncated introns. 
The pE11-mut vector containing the mutagenized CU-rich element of PTB 
exon  11  was  generated  via  a  site-directed  mutagenesis  system  (Quik-
Change; Agilent Technologies). To construct the PTB minigene vector, a 
mouse genomic region spanning from exon 10 to exon 12 of PTB was ob-
tained by PCR amplification using genomic DNA from ES cells as template, 
and then the PCR product was subcloned into pCH110 (GE Healthcare) to 
replace the -galactosidase gene. All primers used in this study are listed 
in Table II.
Cell culture, differentiation of myoblasts, and cycloheximide treatment
Mouse C2C12 cells were maintained in DME (Invitrogen) supplemented 
with 10% fetal bovine serum (Invitrogen). To induce C2C12 cell differentia-
tion, the medium contained 2% horse serum and 20 µg/ml insulin. To block 
the NMD pathway, the cells were treated with 100 µM cycloheximide for 
2 h before harvest.
Transfection and in vivo splicing assay
C2C12 cells were grown to 50–60% confluency in 6-well plates and trans-
fected using Lipofectamine 2000 (Invitrogen). In general, 0.5 µg of each 
reporter alone or together with 2 µg of expression vector encoding the 
FLAG-tagged splicing effector was transfected into C2C12 cells for 24 h. 
To examine the effect of cell differentiation or trans-acting factors on splic-
ing of endogenous PTB and nPTB as well as other muscle-specific prem-
RNAs, differentiation was induced for 24 h or 4 µg of effector expression 
vector was transiently transfected for 24 h before cell harvest. Total RNA 
was collected from C2C12 cells using Trizol (Invitrogen). For RT-PCR analy-
sis, 2 µg of RNA was reverse transcribed by SuperScriptase III (Invitrogen) 
in a 10-µl reaction. RT-PCR analysis was performed using appropriate 
sets of primers, and the resulting products were blotted and probed with 
32P-labeled specific primers (see figure legends). Knockdown of RBM4 was 
performed by transient transfection of the vector expressing RBM4-target-
ing shRNA1 (Lin and Tarn, 2009) or shRNA2 (complementary to nucleo-
tides  150–172  of  human  RBM4a).  Knockdown  of  PTB  was  performed 
using pBS-sh1-shPTB (Boutz et al., 2007b).
Immunoblotting
Immunoblotting analysis was conducted as recommended using the en-
hanced chemiluminescence (ECL) system (Millipore), and the images were 
analyzed by the LAS-3000 imaging system (Fujifilm). Primary antibodies used 
in this study include polyclonal anti-RBM4 and anti-pS309, which recognize 
total and phosphorylated RBM4, respectively (Lin et al., 2007); polyclonal 
Overexpression of RBM4 induced either skipping or inclusion 
of the regulated exons, but invariably promoted expression of 
muscle-specific isoforms. Interestingly, except for PTB/nPTB 
and MEF2c transcripts, RBM4 and PTB functioned in opposition 
to modulate muscle-specific exon selection. The MEF2 family 
members are transcriptional enhancers and function upstream of 
myogenin and MyoD in a transcriptional cascade during myo-
genesis (Berkes and Tapscott, 2005, Keren et al., 2006). There-
fore, it is reasonable that RBM4 and PTB, both of which are 
expressed in undifferentiated myoblasts, show the same effect to 
promote the initial steps of myogenesis (Fig. 8 C). However, a 
large fraction of the RBM4/PTB targets we examined function in 
fully differentiated myocytes, including those encoding cyto-
skeletal proteins of actin filaments and receptors that modulate 
muscle cell physiology (Table I). RBM4 and PTB exert opposite 
effects in modulating alternative splicing of these common tar-
gets, as we previously observed with -TM exon selection (Lin 
and Tarn, 2005). Therefore, in order to enhance its effect on pro-
moting muscle cell–specific isoform expression, RBM4 down-
regulates the expression of its functional antagonist, PTB, as 
myoblasts commit to terminal differentiation (Fig. 8 C).
In conclusion, our results indicated that although the ex-
pression level of RBM4 does not increase greatly during muscle 
differentiation, it might strategically down-regulate PTB and 
nPTB in order to raise its level relative to such antagonizing 
factors and thereby potentiate its effect toward expression of 
muscle cell–specific isoforms. Moreover, our data coincidently 
suggested that RBM4 functions positively in muscle cell differ-
entiation in part via its role in alternative splicing.
Materials and methods
Plasmid construction and primers
The mammalian expression vectors for FLAG-tagged RBM4 (wild-type and 
phosphorylation site mutants) and FLAG-ASF and the bacterial expression 
vector  of  His-tagged  RBM4  were  described  previously  (Lin  and  Tarn, 
2005). The expression vectors for FLAG-tagged PTB, nPTB, and dominant-
negative mutant Upf1 were kind gifts of D. Black (University of California, Los 
Angeles, Los Angeles, CA) and J. Lykke-Andersen (University of California, 
Figure 8.  Model for RBM4-mediated control of muscle 
cell–specific  alternative  splicing.  (A)  RBM4  activates 
exon 11 exclusion via binding to exon 11 together with 
its upstream or downstream intron. The resulting prema-
ture termination codon-containing PTB transcripts are tar-
geted for degradation through NMD. PTB activates exon 11   
skipping of its own transcripts via binding to exon 11 
as well as upstream intronic elements. Purple and blue 
rectangles depict representative RBM4 and PTB binding 
sites, respectively. RBM4 and PTB may share a part of 
CU-rich binding sites. (B) RBM4 activates alternative exon 
skipping when it binds simultaneously to both exonic and 
intronic elements, whereas it may promote exon inclusion 
via binding only to (downstream) intronic elements. (C) In 
myoblasts, RBM4 and PTB may function similarly in splic-
ing regulation of the transcripts (such as MEf2c) that are 
expressed at an early stage of differentiation to promote 
muscle cell–specific isoform expression. However, over-
expression of PTB in general suppresses the production 
of mRNA isoforms that are specific to late stages of dif-
ferentiation. RBM4 down-regulates PTB via AS-NMD and 
meanwhile acts oppositely to PTB or antagonizes its sup-
pressive activity in alternative splicing control to achieve 
maximal yield of muscle cell–specific mRNA isoforms.519 A splicing cascade during myogenesis • Lin and Tarn
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anti-nPTB (a kind gift from D. Black) and monoclonal anti-PTB (EMD); anti-
FLAG (Sigma-Aldrich); and anti-tubulin (Thermo Fisher Scientific).
Immunofluorescence
Indirect immunofluorescence was performed essentially according to the 
procedure described in Lai et al. (2003) with monoclonal anti-MHC (Abcam) 
as primary antibody. The specimens were observed using the Radiance 
2100 confocal microscopy system (Bio-Rad Laboratories).
Electrophoretic mobility shift assay
Recombinant His-tagged proteins were prepared as described previously 
(Lin et al., 2007). RNA probes used were PTB exon 11 (E11UD, 57 nucleo-
tides) or exon 11 plus its upstream (E11D, 382 nucleotides) or down-
stream (E11U, 237 nucleotides) intron. Intronic sequences were in vitro 
transcribed and used as probes. For RNA–protein interaction, 1 µg of each 
recombinant protein was incubated with 2 × 10
5 cpm of 
32P-labeled tran-
script (3 × 10
5 cpm/pmol) as described previously (Lin et al., 2007). The 
reactions were analyzed by electrophoresis on a 4 or 6% nondenaturing 
polyacrylamide gel in TBE buffer (45 mM Tris-HCl, 45 mM boric acid, and 
1 mM EDTA, pH 8.0).
Online supplemental material
Fig. S1 shows that blockage of NMD by overexpression of a dominant-
negative mutant of Upf1 caused accumulation of exon 11–skipped PTB   
isoforms  that  were  induced  by  either  differentiation  or  RBM4  over-
expression. Fig. S2 shows that RBM4 activated PTB exon 11 skipping in 
a dose-dependent manner, and that both nonphosphorylatable (SA) and 
phosphomimetic (SD) forms of RBM4 could induce PTB exon 11 skipping. 
However, the slightly lower activity of RBM4-SD was perhaps due to its 
higher  tendency  to  cytoplasmic  distribution.  Fig.  S3  shows  that  knock-
down of RBM4 compromised differentiation-induced PTB exon 11 skip-
ping. Fig. S4 shows that RBM4 could activate exon 11 skipping of a PTB 
minigene transcript. Fig. S5 shows that recombinant RBM4 could bind to 
different PTB mRNA fragments containing exon 11 and might even form 
multimers. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201007131/DC1.
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